{"key":"tirzepatide","slug":"tirzepatide","name":"Tirzepatide","other_names":["LY3298176","Tirz"],"kind":"single","area":{"slug":"metabolic","name":"Metabolic"},"classification":"Dual GIP and GLP-1 receptor agonist","standing":{"id":"approved","label":"Licensed medicine","rank":5},"summary":"A single peptide that acts on the GIP and GLP-1 receptors, given once weekly. It is a licensed medicine for type 2 diabetes and for weight management.","cas_number":"2023788-19-2","molecular_formula":null,"molecular_weight":"4813.5 g/mol","components":[],"has_article":false,"pubmed":{"papers":2794,"in_humans":1501,"clinical_trials":146},"retired":false,"updated_at":"2026-11-18T00:17:24.691Z","url":"https://pepts.wiki/compounds/tirzepatide","article":null,"evidence":{"query":"(\"Tirzepatide\"[tiab])","fetched_at":"2026-11-16T23:09:01.438Z","counts":{"rcts":135,"human":1501,"total":2794,"reviews":1024,"clinicalTrials":146},"years":[{"year":2012,"count":2},{"year":2013,"count":0},{"year":2014,"count":0},{"year":2015,"count":0},{"year":2016,"count":0},{"year":2017,"count":0},{"year":2018,"count":0},{"year":2019,"count":0},{"year":2020,"count":10},{"year":2021,"count":36},{"year":2022,"count":112},{"year":2023,"count":221},{"year":2024,"count":394},{"year":2025,"count":901},{"year":2026,"count":1349}],"top":[{"doi":"10.1111/dom.16275","url":"https://pubmed.ncbi.nlm.nih.gov/39996356/","kind":"rct","pmid":"39996356","year":2025,"title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","venue":"Diabetes, obesity & metabolism","authors":"Look M, Dunn JP, Kushner RF, et al."},{"doi":"10.1056/NEJMoa2410819","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/","kind":"rct","pmid":"39536238","year":2025,"title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","venue":"The New England journal of medicine","authors":"Jastreboff AM, le Roux CW, Stefanski A, et al."},{"doi":"10.1056/NEJMoa2404881","url":"https://pubmed.ncbi.nlm.nih.gov/38912654/","kind":"rct","pmid":"38912654","year":2024,"title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","venue":"The New England journal of medicine","authors":"Malhotra A, Grunstein RR, Fietze I, et al."},{"doi":"10.1056/NEJMoa2206038","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","kind":"rct","pmid":"35658024","year":2022,"title":"Tirzepatide Once Weekly for the Treatment of Obesity","venue":"The New England journal of medicine","authors":"Jastreboff AM, Aronne LJ, Ahmad NN, et al."},{"doi":"10.1111/obr.13929","url":"https://pubmed.ncbi.nlm.nih.gov/40186344/","kind":"meta","pmid":"40186344","year":2025,"title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis","venue":"Obesity reviews : an official journal of the International Association for the Study of Obesity","authors":"Berg S, Stickle H, Rose SJ, et al."},{"doi":"10.1001/jama.2023.24945","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","kind":"rct","pmid":"38078870","year":2024,"title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial","venue":"JAMA","authors":"Aronne LJ, Sattar N, Horn DB, et al."},{"doi":"10.1056/NEJMoa2416394","url":"https://pubmed.ncbi.nlm.nih.gov/40353578/","kind":"trial","pmid":"40353578","year":2025,"title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","venue":"The New England journal of medicine","authors":"Aronne LJ, Horn DB, le Roux CW, et al."},{"doi":"10.1001/jama.2022.0078","url":"https://pubmed.ncbi.nlm.nih.gov/35133415/","kind":"rct","pmid":"35133415","year":2022,"title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","venue":"JAMA","authors":"Dahl D, Onishi Y, Norwood P, et al."},{"doi":"10.1016/S0140-6736(21)01324-6","url":"https://pubmed.ncbi.nlm.nih.gov/34186022/","kind":"rct","pmid":"34186022","year":2021,"title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","venue":"Lancet (London, England)","authors":"Rosenstock J, Wysham C, Frías JP, et al."},{"doi":"10.1001/jama.2025.14092","url":"https://pubmed.ncbi.nlm.nih.gov/40886075/","kind":"study","pmid":"40886075","year":2025,"title":"Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction","venue":"JAMA","authors":"Krüger N, Schneeweiss S, Fuse K, et al."}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}